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PathogenesisSIVagm does not induce disease in its African green monkey (AGM) host. In comparison, the hybrid simian-
human immunodeﬁciency virus SHIV89.6P that carries the HIV env gene induces disease in rhesus macaques
more rapidly than the SIVmac parent virus. To address the possibility that this enhancement of disease by
HIV env would also occur when present in SIVagm, a full-length SIVagm/89.6Penv chimeric lentivirus
genome (termed SHIV-MP) was constructed. SHIV-MP replicated similarly to SIVagm in simian peripheral
blood mononuclear cells (PBMCs). In inoculated AGMs, rhesus macaques and pig-tailed (PT) macaques the
absolute number of CD4+ T lymphocytes remained at normal levels. The peak levels of productively infected
cells in SHIV-MP-infected monkeys ranged from 101 to 102 per 106 PBMCs, while in SIVagm infected
macaques the levels were 10–100-fold higher. The env gene of SHIV89.6P therefore appears insufﬁcient to
confer acute pathogenicity to a non-pathogenic primate lentivirus due to poor in vivo replication.f.de (C. Münk).
epatology and Infectiology,
renstr. 5, 40225 Düsseldorf,
ll rights reserved.© 2010 Elsevier Inc. All rights reserved.Introduction
Simian immunodeﬁciency virus (SIV) of African green monkeys
(Chlorocebus sp., AGM), SIVagm, is endemic in AGMs. Despite most
adult AGMs being infected in the wild (Jolly et al., 1996; Kanki et al.,
1985), these natural hosts develop neither the symptoms associated
with acquired immunodeﬁciency nor the acute decline in peripheral
CD4+ T lymphocytes (Hartung et al., 1992; Kanki et al., 1985; Kraus et
al., 1989; Norley et al., 1990). The underlying biological mechanisms
protecting these animals from AIDS remain unclear, despite many
studies investigating the virus-host relationship (Broussard et al.,
2001; Goldstein et al., 2006; Gueye et al., 2004; Muller & Barre-
Sinoussi, 2003). Although it has recently been shown that critical Th
cells may be protected from infection in AGMs by down-regulation of
the CD4 molecule (Beaumier et al., 2009), it has also become
increasingly clear that the major difference between “natural”
apathogenic infections of African primates and the AIDS-inducing
infections of humans and Asian macaques is the lack of hyperimmune
activation in the former. Although the precise biological reason for
this difference has yet to be identiﬁed, there are a number of possiblecandidates (reviewed in (Sodora et al., 2009) and (Liovat et al.,
2009)), including the early dampening of T-cell activation by PD-1
expression (Estes et al., 2008), the maintenance of balance between
Tregs and IL-17-secreting Th cells (Favre et al., 2009), and a lack of
microbial translocation across the gut mucosa (Paiardini et al., 2008).
AGMs belong to the genus Chlorocebus, comprising the four
species vervet (C. pygerythrus), grivet (C. aethiops), sabaeus (C.
sabaeus), and tantalus monkeys (C. tantalus) (for review see (Muller
& Barre-Sinoussi, 2003)). SIVagm subtypes separate according to their
host species (Jin et al., 1994), which reﬂects either a species-speciﬁc
viral adaptation to host factors or a long period of co-evolution of virus
and host from common ancestors (Allan et al., 1991; Fomsgaard et al.,
1997).
Despite its benign nature in the natural AGM host, SIVagm is not
per se apathogenic. In heterologous primate species in which
replication is supported to a sufﬁcient degree, particular isolates of
SIVagm will induce the typical symptoms of simian AIDS (Goldstein
et al., 2005; Hirsch et al., 1995). One SIVagm isolate (SIVagm9063)
induced fatal immunosuppressive disease in one out of four inoculated
pig-tailed (PT) macaques (Gravell et al., 1989). This and another
isolate was shown to cause a signiﬁcant decrease in CD4+ T cell count
in PTmacaques (Goldstein et al., 2005; Johnson et al., 1990), andmost
experimentally infected PT macaques developed an AIDS-like disease
within 4 to 24months, paralleled by a rapid decrease in the number of
circulating CD4+ T cells (Hirsch et al., 1995). Indeed, as with SIVmac in
rhesus macaques and HIV-1 in humans, the degree of pathogenicity is
Fig. 1. Viral genome structure of SHIV-MP. Sequences corresponding to SIVagm3mc (GenBank accession no. M30931) are shown as open boxes (nucleotides 1–5766 and 8127–8962)
and those corresponding to SHIV-89.6P KB9 (GenBank no. U89134) as shaded boxes (nucleotides 6158–8687).
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this general rule does not seem to apply to macaques infected with
SIVl'hoest and SIVsun (Beer et al., 2005). Again, similarly to the
situation with isolates and molecular clones of SIVmac, there are
isolates and clones of SIVagm that do not replicate to a high degree
and do not induce AIDS in the heterologous species. One typical
example for such an apathogenic SIVagm is SIVagm3mc, molecularly
cloned from an isolate derived from an Ethiopian AGM of the vervet
subspecies (Baier et al., 1989). SIVagm3mc is pathogenic in neither
AGMs (adult and newborn) nor PT macaques (Baier et al., 1989; Beer
et al., 1996; Beer et al., 1998; Norley et al., 1990).Fig. 2. Comparison of replication in a human T cell line. (A) C8166 cells, a transformed huma
triangles). Virus production (reverse transcriptase activity in culture supernatants) was m
experiments. (B) SHIV-MP infected C8166 cells (right panel) developed syncytia (arrow), wTo facilitate the testing of HIV-1 Env-based vaccines in primates,
various simian-human immunodeﬁciency viruses (SHIVs) containing
HIV-1-derived segments in a simian immunodeﬁciency virus back-
ground have been produced. The mostly widely used and best
characterized SHIV (SHIV89.6P) was generated by passage of the
SHIV89.6 clone (containing the tat, rev, vpu, and env genes of HIV-1 in a
SIVmac239 background) through rhesus macaques (Reimann et al.,
1996a; Reimann et al., 1996b). Unlike SIV and most early isolates of
HIV-1, which utilize the CCR5 co-receptor for infection, SHIV89.6P is
CXCR4-tropic (Zhang et al., 2000). Studies have demonstrated that the
degree of CD4+ T cell depletion following infection is determined byn T-cell line, were infected with either SHIV-MP (black squares) or SIVagm3mc (white
easured over the course of 14 days. Shown data represent one of three independent
hile cells infected with SIVagm3mc (left panel) did not.
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this depletion correlated with the capacity of the virus to induce
membrane-fusion in cultured T lymphocytes (Etemad-Moghadamet al.,
2000; Etemad-Moghadam et al., 2002). Infection of rhesus macaques
with SHIV89.6P results in a rapid depletion of CD4+ T cells within 2–
4 weeks, followed by an AIDS-like disease (Reimann et al., 1996a).
Given the apparent role played by the HIV-1-derived env in the
enhanced pathogenicity of the SIVmac-based SHIV89.6P, we wished
to ascertain whether the same gene in the background of an
inherently apathogenic SIVagm isolate would increase the pathoge-
nicity of the virus. In this study we therefore describe the inoculation
of three different monkeys species (AGM, PT macaques, rhesus
macaques) with the novel SHIV-MP, an SIVagm3mc-derived virus
containing vpu and env from SHIV89.6P. The in vitro replication
kinetics of SHIV-MP and SIVagm3mc in T cells were found to be
similar, but in stark contrast the in vivo replication of SHIV-MP was
relatively poor.
Results
Generation of an infectious SHIV based on SIVagm
Because the HIV-1 89.6-derived envelope gene is known to be
associated with an increased T cell depletion in infected macaques
when combined with a normally pathogenic SIVmac to give the SHIV-
89.6P (Karlsson et al., 1997; Reimann et al., 1996a), we decided toFig. 3. Comparison of viral replication in simian PBMCs. PHA-stimulated PBMCs from (A) AGM
squares) or SIVagm3mc (white triangles). Virus production (reverse transcriptase activity in
two (AGM 384, PT 6495 and Rh 9214) or three experiments (AGM B11, AGM B14, PT 337,investigate the possible induction of disease by such a “pathogenic”
envelope gene when part of the normally apathogenic virus SIVagm
(Baier et al., 1989; Fukasawa et al., 1988; Kraus et al., 1989; Norley et
al., 1990). SIVagm3mc was used to produce a recombinant chimeric
SHIV-MP, containing the env of SHIV89.6P (Fig. 1). To ensure proper
transactivation of the LTR of SHIV-MP, we decided to keep part of the
tat gene of SIVagm, although the 3′ part of the tat exon 1 and exon 2
were derived from SHIV89.6P. In addition to the HIV-1-derived env
gene of SHIV89.6p, we included vpu to maintain the ability to
replicate in tetherin expressing human cells (Neil et al., 2008;
Varthakavi et al., 2003). The sequence derived from the SHIV89.6P
extended to the middle of the second exon of rev, encompassing the
critical ectodomain and cytoplasmic tail changes relevant for disease
induction (Karlsson et al., 1998). As a result of this cloning strategy,
the tat and rev genes encoded chimeric proteins.
Replication of SHIV-MP in simian PBMCs
To ensure that the generated SHIV-MP plasmid encodes an
infectious genome, 293T cells were transfected with pSHIV-MP or
pSIVagm3mc. Culture supernatants from transfected cells were
normalized for reverse transcriptase (RT) activity and used to infect
permissive cells. First, C8166 cells were infected with 500 pg RT of
either SIVagm3mc or SHIV-MP. Replication kinetics over 14 days were
similar for both viruses (Fig. 2A). However, whereas SIVagm3 infected
cells developed only minor cythopathic changes, SHIV-MP induceds, (B) PT macaques and (C) rhesus macaques were infected with either SHIV-MP (black
culture supernatants) was measured over the course of 14 days. Representative data of
PT R4, Rh 274 and Rh 92171) are shown.
90 M. Perković et al. / Virology 399 (2010) 87–97dramatic syncytia formation (Fig. 2B), consistent with the properties
described for the original SHIV89.6P (Etemad-Moghadam et al.,
2000). This suggested that the syncytia-forming ability of the 89.6P
env expressed in SHIV-MP remained functional. The in vitro
replication of SHIV-MP was also examined in PHA activated/IL-2
stimulated simian PBMCs. SHIV-MP appeared to replicate better in
the PBMCs of pig-tailed and rhesus macaques than did SIVagm3mc
(Fig. 3). The opposite was seen in AGM PBMCs: SHIV-MP replicated
poorly compared to SIVagm3mc.
SHIV-MP replicates poorly in vivo
Two PT macaques (PT278 and PT309), two rhesus macaques
(Rh286 and Rh291), and two AGMs (AGM5321 and AGM5446) were
infected with 5×105 tissue culture infective doses (TCID50) of SHIV-
MP. As a comparison, two PT macaques (PT298 and PT6495) were
infected with 5×105 TCID50 of the parental virus, SIVagm3mc.
Samples of peripheral blood were drawn weekly during the ﬁrst
7 weeks after inoculation and every second month thereafter until
week 100 or 110.
The kinetics of infection in vivo were determined by measuring
plasma viral loads (viral RNA and p27 capsid protein) and the number
of productively infected cells in peripheral blood by limiting dilution
co-culture with susceptible indicator cells. Viral RNA (Fig. 4A) became
detectable at week 1 in both SHIV-MP-infected PT macaques and at
weeks 1 and 2 in those infected with SIVagm3mc. Peak levels ranged
from 3×103 to 2×106 RNA copies/ml of plasma but dropped underFig. 4. Plasma virus load during the acute phase of infection. Virus loads in the plasma of
animals infected with SHIV-MP (PT278, PT309, Rh286, Rh291) or SIVagm3mc (PT298,
PT6495) were measured by (A) real-time quantitative RT-PCR and (B) p27 antigen
trapping ELISA. Animals with undetectable plasma viral load are not depicted.the detection limit by week 4. Curiously, despite being based on
SIVagm, the replication of SHIV-MP in AGMs failed to reach detectable
levels at any time. Viral RNA was only detectable in the SHIV-MP
rhesus macaques at one time point, one at 3 weeks and the other at
5 weeks.
The pattern of capsid p27 protein levels in plasma as measured by
antigen-capture ELISA (Fig. 4B) approximately followed that seen for
viral RNA although both the AGMs and rhesusmacaques infected with
SHIV-MP remained under the detection limit. The reason for the
discrepancy between the peak plasma virus load in PT6495 as
measured by viral RNA (week 3) and p27 (week 2) is unknown, but
is probably due to accumulated differences in the sample processing
and assays rather than representing an actual biological phenomenon.
The patterns of cell-associated viral load were somewhat different
than that of the plasma viral load. In the SHIV-infected PT macaques
(Fig. 5A) peaks of 20–200 infected cells per 106 PBMC were seen at 3
or 4 weeks p.i. and generally remained at 10 infected cells or less over
the course of 2 years with a ﬁnal decline. There was a similar pattern
in the SHIV-infected rhesus macaques (Fig. 5B) (albeit with a less
prominent peak during the early phase) although, unlike the pig-
tailed macaques, the rhesus were already isolation-positive at 1 week
p.i. It should be noted that, as all animals had some time earlier been
shown to seronegative for SIV, no cocultures were set on the day of
inoculation. With one exception, all animals were indeed shown
retrospectively to be seronegative and plasma virus negative at 0w.p.i.
However, although negative by RT-PCR, plasma from the SHIV-
inoculated AGM5321 was found to already contain SIV-speciﬁc
antibodies at the time of inoculation (Fig. 7), and subsequent co-
culture of PBMCs frozen at an earlier time-point conﬁrmed a pre-
existing, natural infection with SIVagm. Conclusions concerning the
pattern of cell-associated virus load in SHIV-infected AGMs are
therefore based on only one animal (Fig. 5C), but it is striking that
this animal showed no acute virus peak, but instead only became
consistently positive after week 10. Finally, pig-tailed macaques
infected with the parental SIVagm3mc showed a rapid and compar-
atively high (103–104 infected cells per million PBMC) acute peak that
steadily declined over the ensuing 10 weeks to levels similar to those
seen for the SHIV-MP infected animals.
Absence of pathogenicity in monkeys infected with SHIV-MP
SHIV-MP inoculated AGMs showed no signiﬁcant changes in the
absolute numbers of peripheral CD4+ T lymphocytes during the ﬁrst
5 weeks post-inoculation (p.i.) and remained (with some ﬂuctua-
tions) close to preinoculation values (100 – 300 CD4+ T cells/μl
blood) until week 110 (Fig. 6C). Whereas SHIV-inoculated PT309 also
maintained CD4+ cells, PT278, after an initial increase, showed a
constant decline to 50% of the initial counts by week 6 where they
remained until week 110 p.i. (Fig. 6A). The SHIV-infected rhesus
macaques, despite ﬂuctuations, had CD4 counts after 2 years at least
as high as pre-infection values (Fig. 6B).
Pig-tailed macaques infected with the parental virus SIVagm
(PT298 and PT6495) underwent a dramatic early decline in CD4+ T
lymphocyte numbers (to 20–30% of the initial numbers) but in the
following 3 weeks the absolute numbers of the CD4+-lymphocytes
increased to 50–70% of the levels before virus inoculation where they
remained, with ﬂuctuation, for the rest of the study period (Fig. 6D).
During 28 months of observation, none of the SHIV-MP- or
SIVagm3mc-inoculated monkeys showed any clinical signs of disease.
No evidence for vigorous immune control
As shown in Fig. 7, SHIV-infected pig-tailed macaques serocon-
verted at 5 w.p.i and levels of binding antibodies plateaued by week 7.
Those infected with the SIVagm3mc became positive at week 4
(consistent with the earlier peak in cell-associated virus load) and
Fig. 5. Cell-associated viral loads. The numbers of infected cells in the peripheral blood of animals inoculated with SHIV-MP (PT278, PT309, Rh286, Rh291, AGM5321, AGM5446) or
SIVagm3mc (PT298, PT6495) were measured by co-cultivation of serially diluted PBMCs with C8166 indicator cells for 2 weeks before detection of infected cells by
immunoperoxidase staining.
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week 16. As mentioned previously, AGM5321, inoculated with SHIV-
MP, was already seropositive at 0 w.p.i. due to a recent but pre-
existing natural infection, but the second SHIV-inoculated AGM5446
remained seronegative during the ﬁrst 16 weeks, which is again
consistent with the very low levels of infection during this period. The
titres of antibodies in the SHIV-inoculated rhesus macaques ﬂuctu-
ated between negative and slightly positive (data not shown).
Although SIVagm is itself known to be resistant to neutralising
antibodies (Norley et al., 1990), it was possible that the HIV-1
envelope glycoprotein would render the virus susceptible. Sera from
all animals were therefore tested for their ability to neutralise SHIV-
MP in vitro. However, despite using an assay that is usually exquisitely
sensitive, at no time point did any of the sera demonstrate the
presence of antibodies able to neutralise the infectivity of SHIV-MP
(data not shown).
Finally, attempts were made to measure the T-cell mediated
immune response to the SIVagm Gag protein (common to both SHIV-
MP and SIVagm3mc) in infected animals (Fig. 8) (except PT278, which
had in the meantime been euthanized for reasons unrelated to the
infection). ELISpot assays were performed in which PBMC taken
approximately 3 years after inoculation were incubated with pools of
overlapping synthetic peptides arranged in a matrix (so that each
peptide was present in two unique pools). Peptide-speciﬁc responses
could be detected in none of the SHIV-MP infected animals and even
the strong response seen in the pre-infected AGM 5231 to pool 2 must
be take as non-speciﬁc as no such reaction was seen in any of the
other pools containing the same peptides. Only PT298, infected with
SIVagm3mc gave positive signals in corresponding pairs of pools (P1,
P5, P13 and P14), which indicated an epitope within the individual
peptides 3 and 4 plus 43 and 44 (Fig. 8). The reactivity was conﬁrmedfor peptides 43 and 44 using the single peptides in the ELISpot assay,
but could not be unequivocally conﬁrmed for the single peptides 3
and 4 (data not shown). These data indicate that a T-cell epitope for a
Macaca nemestrinaMHC haplotype exists in the overlapping region of
peptides 43 and 44, i.e. in SIVagmGag216–225, IINEEAAQWD.
In summary, despite possessing an envelope glycoprotein associ-
atedwith rapid CD4+ T cell depletion and simian AIDSwhen part of an
SIVmac genome, the SIVagm-based SHIV-MP caused neither acute nor
long term pathogenicity. Indeed, the levels of replication in all three
species of primate appeared to be lower than that of SIVagm (in pig-
tailed macaques). There was, however, no indication that these lower
virus loads were caused by susceptibility to a particularly vigorous
immune response.
Discussion
The reason why the various forms of SIV are non-pathogenic in
their natural African primate host species while able to induce AIDS in
heterologous hosts such as Asian macaques or humans remains
unclear. However, recent studies demonstrate that the natural host
species do not develop the state of hyperimmune activation
characteristic of HIV-1 infection of humans and SIVmac infection of
macaques (Chakrabarti, 2004; Cumont et al., 2008; Liovat et al., 2009;
Zahn et al., 2008). If continuous immune activation is the underlying
cause of AIDS, possibly by driving the immune response to
exhaustion, then the natural hosts (or their viruses) may have
evolved a state in which the immune system tolerates what is
effectively a lifelong acute infection without responding with an
inappropriate and ultimately damaging response. If so, elucidating the
biological basis for this phenomenon could have important implica-
tions for the treatment of AIDS.
Fig. 6. Absolute numbers of circulating CD4+ T lymphocyte in infected animals. CD4+ T lymphocytes per μl peripheral blood in (A) PT macaques, (B) rhesus macaques, and (C) AGMs
infected with SHIV-MP or in (D) PT macaques infected with SIVagm3mc were determined by ﬂow cytometry.
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causes a “cytokine storm” and rapid death in macaques (Israel et al.,
1993; Schwiebert & Fultz, 1994), the SIV/HIV hybrid virus SHIV89.6P
causes a rapid onset of AIDS-associated symptoms, particularly a
profound loss of CD4+ lymphocytes (Reimann et al., 1996a). This is
contrast to the more gradual onset of disease typical of infection with
the isolate of SIVmac upon which the SHIV89.6P is based (Naidu et al.,Fig. 7. Development of speciﬁc antibodies. Titres of antibodies speciﬁc for SHIV-MP
(PT278, PT309, AGM5321, AGM5446) or SIVagm3mc (PT298, PT6495) during the
course of acute infection was measured by ELISA using whole virus lysate to coat plates.1988). The HIV-1 envelope protein expressed by the SHIV is therefore
considered to be associated with this acute disease.
It therefore seemed possible that a normally non-pathogenic virus
such as the SIVagm3mc clone, when expressing the SHIV89.6P enve-
lope gene in place of its own,might lose its non-pathogenic phenotype
in macaques or even in its natural African green monkey host, either
by disturbing (in the case of AGMs) the benign virus/host relationship
that has evolved over millennia and/or by causing the acute loss of
CD4+ cells that is associated with the foreign envelope glycoprotein.
To test this hypothesis, a recombinant virus termed SHIV-MP,
comprising SIVagm3mc but with the env gene of SHIV89.6P (plus vpu
and sections of rev and tat), was constructed and initially tested for
replication in vitro. The virus was found to replicate as well as wild-
type SIVagm in the permissive C8166 cell line and, in concordance
with the profound effect of SHIV-89.6P on CD4+ cells in vivo, was
shown to readily induce cytopathic effects in the form of syncitia
(Fig. 2). Furthermore, in rhesus and pig-tailed macaque PBMC, the
recombinant virus replicated to much higher levels than SIVagm,
although the reverse was true for AGM PBMCs (Fig. 3).
The virus was therefore used to infect the three different primate
species: natural AGM hosts and the two heterologous Asian macaque
species. For comparison, two pig-tailed macaques were also infected
with the parental SIVagm3mc. In contrast to the results in vitro, none
of the animals inoculated with SHIV-MP showed a profound loss of
CD4+ cells (Fig. 6) despite considerable ﬂuctuation over the course of
2 years. Indeed, the most dramatic 'acute' loss in CD4+ cell numbers
was seen in the two pig-tailed macaques inoculated with the non-
pathogenic, parental SIVagm3mc.
This probable reason for this lack of acute CD4+ cell loss is revealed
by the measurements of plasma and cell-associated viral load (Fig. 4).
Fig. 8. T cell responses to SIVagm Gag. PBMCs taken from infected animals at 2 years post-infection were tested in γ-IFN ELISpot for reactivity to matrix panels of overlapping
synthetic peptides corresponding to the SIVagm3 Gag protein.
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viremia that, in most cases, dropped under the detection limit by
week 4. The results of the limiting dilution co-culture assay for
productively infected cells (Fig. 5), which has a theoretical sensitivity
of approximately 1 infected cell per million PBMC, also showed
macaques infected with the SHIV-MP to have an early appearance of
infected cells by 1–2 weeks that remained at approximately 10
infected cells/million PBMC before declining after 2 years infection.
The pattern in the one 'naïve' AGM infected by the SHIV was very
different, however, with a transient 'blip' above the detection limit at
week 5 and persistent infection only detected after week 10. This is in
agreement with the negative plasma RT-PCR and p27 data for the ﬁrst
8 weeks and despite the SHIV being based on the SIVagm, suggests a
need for an in vivo adaptation in AGMs not necessary in the two
macaque species. The fact that the pig-tailed macaques infected withthe parental SIVagm3mc showed peak cell-associated virus loads
approximately two orders of magnitude higher that those experi-
enced by the SHIV-MP infected macaques underscores the conclusion
that substituting part of the SIVagm genome with that of HIV had
reduced the replicative capacity of the virus and hence its potential to
induce disease.
It seems unlikely that this loss of replicative capacity is due solely
to characteristics of the HIV outer envelope glycoprotein because the
89.6P Env does not hinder high virus loads in macaques when part of
the original SHIV89.6P (Barouch et al., 2000). However, env was not
the only SIVagm gene altered during construction of the SHIV-MP. As
well having the entire SHIV89.6P vpu gene (also no hindrance to high
viral loads in macaques) the rev and tat genes of SHIV-MP are
essentially hybrid constructs of the two viruses. Although not
detrimental in vitro when growing in T cell lines or stimulated
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perform functions essential for efﬁcient replication in vivo. Such a
phenomenon is well known for viruses carrying debilitating muta-
tions in the nef gene, for example (Almond et al., 1995; Daniel et al.,
1992; Kestler et al., 1991; Wyand et al., 1996).
Another possible reason for the relatively low virus loads achieved
by the SHIV-MP in vivo is susceptibility to, or induction of, a
particularly strong immune response. However, in terms of binding
antibodies, the response to the SHIV in pig-tailed macaques was both
slower and weaker than that to SIVagm (Fig. 7). With regards to
functionality, SIVagm is known to be insensitive to neutralising
antibodies whereas SHIV89.6P is fully susceptible, and the exchange
of outer envelope glycoproteins could have rendered the former
vulnerable to neutralisation. However, using a sensitive assay for
neutralisation, the SHIV remained unaffected by the speciﬁc anti-
bodies present in the sera of infected animals. Finally, as a measure of
T cell responses, ELISpot assays were used to measure the frequencies
of T cells reactive to the presence of SIVagm Gag peptides (a gene
common to both the SHIV and the parental SIVagm3mc). The T cell
response to SIVagm Gag is known to be relatively weak and transient
in SIVagm infected AGMs (Lozano Reina et al., 2009; Norley et al.,
1990), but vigorous and prolonged in SIVmac infected macaques
(Sopper et al., 1993). However, none of the macaques infected with
SHIV-MP had detectable Gag-speciﬁc T-cell responses 2 years after
infection. Indeed, the only response was seen in one of the pig-tailed
macaques infected with the parental SIVagm3mc, a response that
allowed the identiﬁcation of a novel T-cell epitope.
Conclusions
In conclusion, despite replicating well and inducing cytopathic
effect in vitro SHIV-MP, a hybrid virus based on apathogenic SIVagm
expressing the 'pathogenic' SHIV89.6P envelope gene, replicated
poorly in all three primate species tested: i.e. two AIDS-susceptible
macaque species and the 'disease-resistant' AGM natural host. This
relatively low-level of replication probably accounts for the weak
immune responses induced in response to infection and for the lack of
disease in the animals. Although the 89.6P envelope glycoprotein may
be associated with acute CD4+ T cell loss and disease in macaques
when carried by an efﬁciently replicating virus such as SIVmac, it is
alone insufﬁcient to transform a non-pathogenic virus into an acutely
pathogenic virus. It is possible that, if the SHIV-MP were to be serially
passaged in macaques (and even in AGMs), the replicative defects in
the virus, which are probably a consequence of its hybrid genome,
would be overcome by adaptation to yield a virus able to replicate to
high levels. Indeed, such in vivo passage was necessary to transform
the original poorly replicating SHIV89.6 to the acutely pathogenic
SHIV89.6P. Only with such an adapted virus could the possible role of
the 89.6P envelope glycoprotein in disease induction when part of an
SIVagm backbone be addressed objectively.
Materials and methods
Plasmids
The complete sequence of the proviral plasmid clone pSIVagm3mc
(SIVagm3mc) [GenBank accession no. M30931]; has been described
previously (Baier et al., 1989). Construction of the proviral plasmid
clone pSHIV-MP containing vpu-env of SHIV89.6P in the background
of SIVagm3mc: The subgenomic region of provirus pSIVagm3-X4
(described in (Konig et al., 2002)) from SacI to HindIII containing the
3′ half of provirus pSIVagm3-X4 was inserted into the plasmid pUC19
(New England Biolabs, Beverly, USA), after the SapI site within pUC19
was deleted by digestion with TﬁI and religation, resulting in
pUC19ΔSapI-env3-X4. Plasmid pSIVagm3-X4 and primers MB1 (5′-
GCGCGAGCTCCTGTTCCAAGTATGG-3′) and MB2 (5′-GCATTACATG-TACTACTTACTGCTTTTGTTCAGGAAAGCGATCAAGC-3′) (sequences ho-
mologous to the SHIV 89.6P genome in italics) were used to generate a
PCR product named fragment-1.2. Plasmid pKB9, containing proviral
DNA of SHIV-KB9 described in (Karlsson et al., 1997), and primers
MB3 (5′-GCTTGATCGCTTTCCTGAACAAAAGCAGTAAGTAGTACATG-
TAATGC-3′) and MB4 (5′-CTCCAATTGTCCCTCATATCTCC-3′) were used
to generate a PCR product named fragment-3.4. Fragment-1.2 and -3.4
were fused by PCR using primers MB1 and MB4 generating fragment-
1.4 that was cloned into pCR4Blund-TOPO (Invitrogen, Carlsbad, USA)
to obtain plasmid pTOPO-1.4. Plasmid pSIVagm3-X4 and primers MB5
(5′-GGAGATATGAGGGACAATTGGAG-3′) and MB6 (5′-CTTGCAC-
CAGTTGCTCTTCCACAGAAGTTCCACAATCCTCG-3′) were used to gener-
ate a PCR product named fragment-5.6 that was cloned into
pCR4Blund-TOPO to obtain plasmid pTOPO-5.6. Fragment-1.4 and
-5.6 were fused by usingMfeI, cutting at 3′ end of fragment-1.4 and 5′
end of fragment-5.6, and NotI, cutting within vector backbone, to
obtain plasmid pTOPO1.6. After digestion by SacI and SapI, the
fragment-1.6 was subcloned into the plasmid pUC19ΔSapI-env3-X4,
generating a chimeric 3′ half of the provirus. The resulting plasmid
pUC19ΔSapI-env1.6, as well as pSIVagm3-X4, was digested with SacI
and HindIII. The chimeric 3′ half plasmid was ligated with the 5′ half
plasmid of pSIVagm3-X4 to generate pSHIV-MP.
Cells, virus stocks and titration
The human T cell line C8166 was maintained in RPMI 1640
medium containing 10% fetal calf serum and 2 mM L-glutamine
(Biochrom KG, Berlin). Ficoll-enriched PBMC from rhesus macaques
(Macaca mulata) (Rh 9214, 274 and 92171), pigtailed macaques
(Macaca nemestrina) (PT 6495, 337 and R4) and African greenmonkey
(Chlorocebus sp.) (AGM 384, B11 and B14) were stimulated with
0.25 μg/ml phytohemagglutinin (Murex Diagnostics Ltd., Dartﬁeld,
UK) and incubated with 112 international units/ml human IL-2
(Proleukin, Chiron, Emeryville, USA) in RPMI 1640 containing 20%
fetal calf serum and 2 mM L-glutamine for 48–72 h before infection.
For the generation of virus stocks, 293T cells were transfected with
5 μg of the full-length proviral construct pSIVagm3mc or pSHIV-MP
using Lipofectamin 2000 (Invitrogen, Carlsbad, USA). Virus-contain-
ing supernatants were collected 48 h after transfection, aliquoted and
frozen at −80 °C for subsequent in vitro and in vivo infections.
To determine the 50% tissue culture infective doses (TCID50), the
stocks were diluted in threefold steps using RPMI 1640 medium, and
eight 50 μl aliquots of each dilution were added to U-well microtiter
plates containing 2000 C8166 T cells per well in 150 μl. After 7 days
incubation at 37 °C, cells were transferred to poly-L-lysine coated F-96
plates, allowed to adhere, ﬁxed with methanol and subjected to
immunoperoxidase staining to detect SIV antigen-expressing cells
using sera from an SIVagm3mc-infected PT macaque as described
previously (Siegel et al., 1995). The TCID50 was calculated using the
method of Spearman–Kärber (Kärber, 1931; Spearman, 1908).
Replication assay
C8166 cells and simian PBMCs (1–5×106) were infected with an
amount of SIVagm3mc and SHIV-MP corresponding to 500 ng reverse
transcriptase. The culture samples were collected at various time
points for measurement of reverse transcriptase activity using the
Lenti-RT Activity Assay (Cavidi Tech, Uppsala, Sweden).
Animals, infections and specimen collection
All animal experiments were performed in accordance with
paragraph 8 of the German Animal Protection Law in compliance
with EC Directive 86/609, which makes it an offence to carry out any
scientiﬁc procedure on an animal except under license. PT macaques
(PT 278, 298, 309 and 6495), rhesus macaques (Rh 286 and 291) and
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intravenously with 5×105 TCID50 of the respective virus stocks. At
regular intervals, citrate blood samples were taken and plasma and
PBMCs were separated immediately by Ficoll-Histopaque density
centrifugation. A portion of the PBMCs were used for the limiting-
dilution coculture assay. The rest was stored at−80 °C as 5×105 cell
pellets. Plasma was clariﬁed by centrifugation and 500 μl aliquots
were frozen at−80 °C until used for themeasurement of plasma virus
load and for the quantitative RT-PCR (qRTPCR) assay. Serum was also
clariﬁed of cells by centrifugation and stored at −20 °C. EDTA blood
samples were used for analysis of absolute numbers of leukocytes per
microliter of blood using Caltag Counting Beads (Caltag, Burlingame,
Kanada) and ﬂow-cytometry analysis.
Flow cytometry
Lymphocyte subsets from PT macaques, rhesus macaques and
AGM were analyzed by FACScan (Becton Dickinson, Heidelberg,
Germany). Ten microliters of the monoclonal antibodies anti-human
CD4 (PerCP conjugated, clone SK3) (Becton Dickinson), anti-human
CD8 (PE conjugated, clone SK1) (Becton Dickinson) and anti-human
CD3 (FITC conjugated, clone SK34) (Becton Dickinson) were incubat-
ed with 100 μl citrate blood samples. AGM PBMCs were stained with
anti-monkey CD3 (FITC conjugated, clone FN-18) (Biosourse, Camar-
illo, USA) in place of anti-human CD3. Erythrocytes were lysed using
Cal-Lyse (Caltag, Burlingame, Kanada) and deionized water. After
adding 100 μl Caltag counting beads, cells were washed with PBS-0.1%
NaN3-10% fetal calf serum and ﬁxed with PBS-1% paraformaldehyde.
The number of events in each of the appropriate gates was obtained
and the absolute counts in relation to the number of beads calculated
using the following formula:
Final absolute count=(number of cells counted / total number of
beads counted)×number of beads per μL (known concentration)
Measurement of cell-associated virus load and virus identiﬁcation
The cell-associated virus load was determined by limiting-dilution
coculture. Five-fold dilutions of PBMCs, starting with 106, were
cocultivatedwith 106 C8166 T cells in triplicate in 24-well plates. After
14 days, the cells were tested for infection by immunoperoxidase
staining. The number of infected cells/106 PBMCs was calculated with
a Poisson distribution ﬁtting model. Virus identiﬁcation was
performed by PCR on genomic DNA, extracted from 106 C8166
cocultivated with PBMCs, using either primer combination MB7
(AGATTGCTCCGCTTGATCGC) and MB8 (GAGTGGGGTTAATTTTACAC)
speciﬁc for SHIV-MP or primer combination MB7 andMB9 (GATCTCT-
TACATACCCTGCC) speciﬁc for SIVagm3mc.
Measurement of viral antigen in plasma
The concentration of SIV p27 core antigen in plasma from infected
animals was determined by using a commercial kit (p27 Antigen
ELISA, ZeptoMetrix, Buffalo, USA).
Measurement of plasma virus load and proviral load
Viral RNA was quantiﬁed using a real-time qRT-PCR assay
monitored in real time using the Mx4000 cycler (Stratagene) as
described previously (Holzammer et al., 2001). RNA was isolated
using the High Pure Viral RNA kit (Roche Molecular Biochemicals,
Mannheim, Germany) eluting in 50 μl of RNase-free water. The
primers SIVagmf (CAG ATG CTC GCT GGC TTG TA) and SIVagmr (GCC
AAC CAG GTT AGG CTA ACC) were speciﬁc for the LTR of SIVagm3mc.
The ﬂuorogenic probe SIVagmp (6-carboxyﬂuorescein [FAM]-AAC
ACC CAG GCT CAA GCT GGT CTC CTA GT-TAMRA [6-carboxytetra-
methylrhodamine]) hybridizes to a region 13 bp 5′ of SIVagmf. PCRswere performed in MicroAmp Optical 96-well plates (PE Applied
Biosystems), and the products were subjected to one-step RT-PCR
cycling. Samples were tested in triplicate, and the number of RNA
copies was determined by comparison with a standard curve obtained
using plasma spiked with 10-fold dilutions of SHIV-MP. Proviral DNA
was also quantiﬁed by real-time PCR. DNA was isolated from 5×105
PBMC using the QIAamp DNA Blood Mini Kit (Qiagen, Hilden,
Germany). Samples were analysed in a multiplex RT-PCR in which
the same primers and ﬂuorogenic probe described above for SIVagm
were used and in parallel, primers and probes corresponding to the
single copy gene HBMS (HMBS-F GCC TGC AGT TTG AAA TCA GTG;
HMBS-R CGGGACGGG CTT TAG CTA; HMBS-P HEX-TGGAAG CTA ATG
GGA AGC CTG GTA CC-TAMRA. Samples were tested in triplicate, and
the number of DNA copies was determined by comparison with a
standard curve obtained using known copy numbers of SHIV-MP
plasmid DNA.
ELISA
Whole, lysed inactivated virus (SIVagm3 or SHIV-MP) at a
predetermined optimal concentration or puriﬁed SIVagm Gag protein
at 0.2 μg/well was diluted in water and dried (overnight; 37 °C) on
Probind (Becton-Dickinson) ELISA plates. The ELISA was then
performed using a standard protocol with titrated sera as described
previously (Barouch et al., 2000). Brieﬂy, the coated plates were
washed with washing buffer (0.05% Tween 20 in PBS) and incubated
with blocking buffer (2% milk powder in PBS) followed by the
addition of titrated sera diluted in blocking buffer plus 0.05% Tween
20. After incubation for 1 h at 37 °C, the plates were washed and
incubated with goat anti-human immunoglobulin G-peroxidase
conjugate (Sigma, Deisenhofen, Germany) diluted 1:1,000. Finally,
the plates were washed and incubated with substrate buffer (0.4 mg
of o-phenylendediamine per ml of citrate buffer [pH 6] plus 0.025%
H2O2), after which the reaction was stopped with 1 M H2SO4 and the
optical density at 492 nm was measured. Titres were deﬁned as the
dilution at which the line of best ﬁt to the titration data intersected
the cut-off OD (mean of negative sera plus 5×SD).
Measurement of neutralising antibodies
Ten microliters of heat-inactivated sera diluted 1:25 was
incubated with 10 μl of 2-fold dilutions of SHIV-MP or SIVagm
(four replicates per dilution). After 60 min of incubation at 37 °C,
180 μl of medium containing 2×103 C8166 T cells was added to each
well of the microtiter plate. The plates were incubated for 7 days at
37 °C after which the contents of the wells were lysed by addition of
20 μl 2% Tween 20. The presence of viral antigen was then
determined using an antigen trapping ELISA speciﬁc for SIVagm
Gag. The degree of neutralisation (yield reduction) was calculated as
the titre of virus in the absence of serum divided by the titre in the
presence of serum.
Measurement of virus-speciﬁc T cells
PBMC taken at 3 years post-infectionwere tested for their ability to
react to SIVagm Gag-speciﬁc peptides in a γ-interferon ELISpot assay.
Brieﬂy, 200,000 PBMC were incubated in triplicate in anti-γ-
interferon antibody (Mab GZ-4) coated PVDF-membrane plates with
15mer peptides spanning the SIVagm3 Gag protein (arranged in
matrix pools in which each peptide is present in two unique pools).
After 16 h incubation at 37 °C, plates were washed and incubated for
2 h with the detection antibody (anti-IFNγ Mab 7-B6-1-biotin),
washed, incubated for 1 h with an alkaline phosphatase-streptavidin
conjugate (Mabtech AB) before washing and visualisation of spots
using the BCIP/NBT substrate. After a ﬁnal wash and drying, spots
were counted using an AID ELISpot reader.
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